Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting

Viewing 1-20 of 34 articles

Organ and Tumor Dosimetry of a Novel PSMA-targeted Radioligand Therapy 177Lu-rhPSMA-10.1: Results from a Phase 1 Study

SNMMI 2025: The Clinical Value of the PROSTest to Detect Biochemical Recurrence in Prostate Cancer

SNMMI 2025: Utility of the PROSTest to Predict Response to 177Lu-PSMA Therapy in mCRPC

SNMMI 2025: Illuminating Renal Cancer: CAIX-PET Imaging and the Shift Toward Precision Diagnostics

SNMMI 2025: 68Ga-NYM096 PET/CT in Patients with Metastatic Clear Cell Renal Cell Carcinoma: A Preliminary Study

SNMMI 2025: First Data of a Novel PSMA-Targeting Radiopharmaceutical Compound SMS-5368: Exploratory and Phase 1/2 Results

SNMMI 2025: A Dose-Escalation Study of the Novel PSMA-Targeting Drug 177Lu-P17-088 in Patients with mCRPC

SNMMI 2025: A New Theranostic Target in Prostate Cancer: First Results from Prostatic Acid Phosphatase (ACP3) Imaging with [68Ga]Ga-OncoACP3-DOTA PET in Prostate Cancer Patients and Comparison to [18F]F-PSMA-1007

SNMMI 2025: Revolutionizing Bladder Cancer Treatment: Tolerability and Efficacy of Intravesical RadioMolecularIncubator Theranostics with 177Lu-CXCR4 and 177Lu-3BP-3940 in High-Grade MIBC

SNMMI 2025: Sequencing and Combining Beta and Alpha Targeted Radionuclide Treatments in the Management of Patients with Prostate Cancer

SNMMI 2025: Prospective, Randomized Trial Comparing PSMA PET/CT and MRI-Guided Versus MRI Only-Guided Prostate Biopsy for Identification of Clinically Significant Prostate Cancer

SNMMI 2025: 8-Year Follow-up of Patient Outcomes and Bone Health in Radium-223 Treated Patients: Data from the Global REASSURE Study

SNMMI 2025: A Phase 1 Trial of 61Cu-NODAGA-PSMA I&T for Patients with Prostate Cancer

SNMMI 2025: First-in-Human Study of 225Ac-LNC1011 in Patients with Prostate-Specific Membrane Antigen (PSMA) Positive Prostate Cancer

SNMMI 2025: The Potential Utility of PSMA PET/CT in Prostate Cancer Biochemical Failure - A Global Retrospective Cohort Study

SNMMI 2025: Clinical Protocols to Monitor Efficacy of 177Lu-PSMA Radiopharmaceutical Therapy in mCRPC

SNMMI 2025: Evaluation of PSMA PET/CT Derived Predictors for Treatment Response to 177Lu-PSMA-617: Results from The U.S. Expanded-Access Program

SNMMI 2025: Role of 18F-Fluciclovine PET/CT in Patients with Biochemical Recurrence of Prostate Cancer and a Negative PSMA PET/CT

SNMMI 2025: Three-Tier Risk Stratification of Prostate Cancer by PSMA-PET PROMISE (PPP2): Results from an International Multi-Center Registry Study

SNMMI 2025: PSMA-Bisphosphonate Imaging Agent: First Human Study of 68Ga-P17-079 in Prostate Cancer

1
2